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We have analyzed the mouse melanoma antigen with mono­
clonal antibodies established by syngeneic immunization. To 
further understand the structure of this antigen at a molecular 
level, we have cloned the genomic DNA controlling the 
expression of melanoma antigen by cosmid library trans fec­
tion and a monoclonal antibody. In the process of analyzing 
this DNA fragment we found that it contained a gene related 
T he immune system is well known to distinguish ma­lignancy from normal cells through cell-surface anti­gens and to eliminate tumor cells from the host. How­ever, tumor cells do often escape from this immune defense system. Thus, the analysis of tumor antigen 
and tumor growth mechanisms in animals provides us with a useful 
model system for approaching the issue of why the immune system 
tolerates malignant cells. In other words, this subject is related to 
understanding the mechanism of self tolerance, which is one of the 
major topics in biology. 
As reported in the mouse melanoma system [1], we successfully 
analyzed this delicate self-tolerance mechanism and showed that 
there indeed exists an escape mechanism from the host surveillance 
- namely, the induction of suppressor T cells (Ts) which inhibit 
the generation of cytotoxic T lymphocytes (CTL) against tumor 
cells. Anti-melanoma Ts are selectively induced by soluble mela­
noma antigen secreted from tumor cells, which also directly 
blocked the CTL activity by binding to the antigen receptor of CTL 
in the effector phase. Thus, it became clear that tumor antigen 
works as an active molecule not only in the induction phase of CTL 
responses, but also in the effector phase. The immune system work­
ing in this way seems to be responsible for tumor cells escaping the 
immunologic surveillance system. 
In regard to the concept of "tumor antigen," we also want to 
stress that it must be recognized by the host immune system. We can 
define the molecule that modulates immune responses as a "tumor 
antigen." Therefore, it is not necessary for the antigen to be in any 
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with transformation, which was proved by tumor formation 
in nude mice inoculated with NIH/3T3 transfectants of this 
DNA fragment. We discuss the structure of the gene product 
based on the deduced amino acid sequence of eDNA, which 
maps the genome bearing transformation-related activity. ] 
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way a unique molecule. Similarly, a different structure from that of 
normal cells cannot be a tumor antigen unless it stimulates the host 
immune system. For that reason, syngeneity between tumor cells 
and the host is required for defining the tumor antigen because all 
different structures and molecular organizations might be recog­
nized as tumor specific. Accordingly, we employed a syngeneic 
combination instead of allo- or xeno-immunization to make mono­
clonal antibodies against melanoma antigens. 
C57BL/6 mice were hyperimmunized with syngeneic B16 mel­
anoma cells, and their spleen cells were fused with P3U1 myeloma 
cells in the presence of polyethylene glycol. We successfully devel­
oped two kinds of antibodies, one of which (M562) is specific for 
mouse melanoma and the other (M2590) which reacts to human 
and hamster melanomas, as well as mouse melanomas [2,3]. Thus, 
the latter antibody recognizes the interspecies cross-reactive epitope 
shared by various mammalian melanomas. 
Another important aspect of the melanoma antigen recognized 
by M562 antibody is that it is involved in the metastasis or coloniza­
tion of melanomas. Administration of M562 antibody could 
strongly inhibit the lung colonization of B16 cells injected intra­
venously. However, M2590 or M622 anti-melanoma antibodies 
bearing the same isotype as M562 antibody could not demonstrate 
any inhibitory action [4]. This result indicates that the molecule 
recognized by M562 antibody plays a significant role in experimen­
tal lung metastasis. 
We describe here the properties of the melanoma antigen exam­
ined by our monoclonal antibodies and the isolation of genomic 
DNA controlling the expression of melanoma antigen, as well as 
the transformation. 
Structure of Melanoma Antigen Defined by Monoclonal An­
tibody In order to investigate the murine melanoma antigen, we 
established two kinds of monoclonal antibodies (M2590 and M562) 
by syngeneic immunization of C57BL/ 6 with B 16 melanoma cells. 
The experiment utilizing these antibodies made it clear that mela­
noma antigen not only exists on the cell surface, but also is secreted 
into the culture supernatant as a macromolecule with a molecular 
weight of more than 20,000 kDa. Biochemical data suggested that 
the antigen recognized by M2590 antibody seemed to be a kind of 
glycolipid because the interspecies cross-reactive antigen was suffi­
ciently stable for chloroform/methanol extraction. To determine 
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this fine chemical structure, we examined the antibody reactivity to 
known glycolipids by enzyme-linked immunosorbent assay on sil­
ica-gel thin-layer chromatography [5]. The results indicated that 
M2590 antibody reacted to GM3(NeuAc) and sialylparagloboside 
(NeuAc), but not to other gangliosides such as GM4, 
GM3(NeuGc), GM2(NeuAc), GM2(NeuGc), and sialylparaglobo­
side(NeuGc). Based on the above data, we can conclude that the 
structure recognized by this antibody is NeuAca2-3Galpl-4Glc [5]. 
We confirmed that M2590 antibody actually reacted to GM3 gang­
lioside purified from B 16 cells, as well as chemically synthesized 
GM3(NeuAc)[ 6]. Analysis by mass spectrometry revealed that there 
were no structural differences between the GM3 ganglioside of 
melanoma origin and that from normal tissues. 
On the other hand, mouse melanoma specific M562 antibody was 
seen to recognize protein moiety because it lost the reactivity when 
the antigen was treated with pronase or heat. When the labeled 
soluble materials were immunoprecipitated with M2590 antibody, 
we detected 31, 58, and 80 kDa molecules. Recently we found that 
the M562 epitope is present on the 80-kDa glycoprotein (Sakiyama 
et ai, manuscript in preparation). This result therefore indicates that 
the melanoma antigen recognized by these monoclonal antibodies is 
a complex of GM3 ganglioside and protein molecules. These pro­
tein moieties and the ganglioside seem to be noncovalently asso­
ciated with each other and constitute a huge polymeric configura­
tion in the culture supernatants. 
Because there is no difference in GM3 ganglioside structures 
between tumor and normal tissue, the question is why such a ubiqui­
tous substance can be a tumor antigen. Although we do not have any 
definite answers yet, we speculate that the tertiary structure or the 
epitopic density might be crucial because Nores et al have clearly 
demonstrated by a liposome-lysis assay that M2590 antibody reacts 
with GM3 at high but not low density [7]. Thus, it is likely that the 
GM3 ganglioside in melanoma cells is exposed to a cell surface of 
high density, whereas it is exposed to one of low density in normal 
cells. The protein portion of the antigen may play an important role 
in making the melanoma antigen immunogenic by modifying the 
tertiary structure or increasing the epitopic density. 
Strategy of Genomic DNA Cloning For investigating the mo­
lecular structure and analyzing the precise function of this antigen, 
we attempted to isolate the gene controlling the glycoprotein anti­
gen associated with GM3. Because monoclonal antibody was avail­
able (M562), we transfected a whole genomic library from B 16 
melanoma cells into antigen negative cells and obtained melanoma­
antigen-positive transfectants. The basic procedure is shown in Fig 
1. The cosmid library was constructed and trans fee ted into human 
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Figure 1. Cloning strategy of mouse melanoma antigen by syngeneic 
monoclonal antibody. 
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melanoma cells (SK-Mel 28), which are negative for the expression 
of mouse melanoma antigen detected by M562 antibody. Antigen 
positive transfectants were aseptically selected with a cell sorter 
(FACS IV, Becton Dickinson, Mountain View, CA), and in vitro 
packaging enabled us to rescue the mouse DNA responsible for the 
antigen expression from these transfectants. 
Construction of Genomic Library with Cosmid Shuttle Vec­
tor We constructed a B 16 genomic library with the cos mid vector 
pCV103 [8] harboring the Ecogpt gene, a drug selection marker, 
and the cos sequence of lambda phage origin. This shuttle vector can 
encompass about 40 kb DNA and can be handled like a plasmid. 
The cos sequence is one of the characteristics of this vector, which 
makes it possible to package DNA fragments if they are placed 
between at least two cos sequences. Partially digested B16 DNA 
with Mbo I restriction enzyme was ligated with Bam HI digested 
vector and in vitro packaging was performed to make the genomic 
library [9]. We examined the library size and found that its content 
was 23 times as long as the total length of the mouse genome and 
covered the whole genome with more than 99% probability. 
Rescue of Genomic DNA Fragment from Transfectants We 
have to take several factors into consideration in order to obtain the 
positive transfectants successfully. One of the major points is the 
transfection efficiency. In the case of high molecular weight ge­
nomic DNA transfection Kavathas et al obtained antigen positive 
L-cell transfectants at the frequency of 0.5 X 10-3 by the calcium 
phosphate precipitation method [10]. Because the total length of the 
mouse genome is 3 X 106 kb, they estimated the average length of 
incorporated DNA in L cells at around 1.5 X 103 kb per cell. Sec­
ond, we also have to pay attention to the combination of host cell 
types and transfection procedures. For example, non-phagocytic 
cells have less capacity to take up exogenous DNA by the calcium 
phosphate precipitation method. However, electroporation or pro­
toplast fusion procedures sometimes increase transfection efficiency 
dramatically [11,12]. 
Another factor involved in the expression of incorporated DNA 
is the tissue specificity. Immunoglobulin gene is expressed well in B 
cells, but hardly at all in L cells [13]. Although we know the antigen 
recognized by M562 antibody is specifically expressed on mouse 
melanoma cells, the structure of the antigen molecule has not been 
completely analyzed yet. Therefore, we cannot rule out the possibil­
ity that tissue specific regulation is operative in the expression of the 
melanoma antigen. For that reason we chose human melanoma cells 
as the target for transfection because they would be sure to provide 
all the necessary components for the antigen expression. The deter­
mination of the host cells then leads us to the idea regarding the 
transfection procedure. We employed the protoplast fusion method 
[14] because it gave us the highest transfection efficiency in this 
case. 
Quite recently Chen et al reported an improved transfection 
method of calcium phosphate precipitation [15], in which they used 
a different buffer system while precipitating DNA and incubated 
cells at low CO2 concentration during the DNA incorporation. 
They could obtain more than 10% transfection yield in most types 
of cells and argued that it became possible to trans feet the whole 
cD N A library into desired cells. We also tried their protocol and 
acquired about 5% transfection efficiency in human melanoma SK­
Mel 28. The average copy numbers of incorporated insert DNA in 
our experiments seemed to be about 10 per cell. 
After protoplast fusion, the host cells were cultured in the selec­
tion medium supplemented with mycophenolic acid (10 ,ug/ml) 
and xanthine (250 ,um/ml) [16]. Mycophenolic acid is an inhibitor 
of nucleic acid synthesis, and Ecogpt gene products circumvent this 
blocked pathway by utilizing xanthine. Under this condition trans­
fectants which come to hold the Ecogpt gene by transfection are 
able to survive and proliferate in the selection medium, while un­
transfectants cannot grow and die within 2 weeks. The transfectants 
growing in the selection medium can be expected to possess mouse 
DNA fragments because the Ecogpt gene is linked to mouse DNA. 
We stained these growing cells with fluorescein isothiocyanate 
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Figure 2. Cell surface staining profiles of human melanoma cells trans­
fected with a B16 genomic library. The leftjigure shows the initial staining 
pattern. The arroll's indicate the sequential sorting of MS62 positive trans­
fectants. T141 is control antibody with the same isotype (IgM, K) as MS62 
antibody. 
conjugated M562 antibody and M562 positive cells were sorted out 
by FACS IV (Fig 2). At the initial staining we could hardly observe 
any antigen positive population. However, by repeated cell sortings 
of the fluorescence bright fraction we could enrich the antigen 
positi ve transfectants [10]. From these enriched transfectants we 
extracted genomic DNA and selectively rescued mouse DNA by in 
vitro packaging. Hut, because human DNA lacks the cos sequence, 
it cannot be rescued by that procedure. 
We examined the rescued DNA fragments and classified them 
into three groups (pD2-1, pD2-2, and pD2-7) based on the restric­
tion map. By the transfection of the individual DNA fragments into 
human melanoma cells we showed that one of them (pD2-7), 
34.8 kb in length with 5 Eco RI restriction sites, controlled the 
M562 antigen expression but the two others did not (Fig. 3A,B) 
[17]. 
However, we noticed the instability of the antigen expression of 
transfectants. When we removed the selective pressure of cell sort­
ing, the antigen expression was low. We have not been able to 
determine the reason for this yet, but it might be due to the prefer­
ential deletion of genomic DNA in cosmid vectors because they are 
considered to exist in extrachromosomal forms [18]. To avoid the 
above problem it is important that the intervals of cell sorting are as 
short as possible [17]. 
Transforming Activity ofIsolated Genomic DNA In the pro­
cess of the analysis of pD2-7, we found that this fragment owned 
another biologic property besides the melanoma antigen expression 
- namely, transformation-related activity. We have investigated 
this activity by way of tumor formation in nude mice. When we 
inoculated 105 pD2-7 transfectants of NIH/3T3 subcutaneously, 
tumors arose at the inoculation sites in about 1 month. However, 
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transfectants with the pCV103 vector as a control did not result in 
any tumors in such a period. 
To narrow down this activity to smaller DNA, we prepared dele­
tion mutants of pD2-7 by partially digesting the ON A with the Eca 
RI restriction enzyme and religating them. We could then success­
fully attribute this to the 9.4-kb DNA subfragment. In order ta 
identify the structure gene within this genomic DNA, we per­
formed Northern blot analysis on B16 melanomas RNA and found 
that 18S RNA was detected with this subfragment as a probe. Then, 
we screened a eDNA library of B16 melanoma origin with this 
probe and cloned a eDNA (02-18) which was mapped to 9.4 kb 
genomic DNA. The nucleotide length of 02-18 corresponded to 
the size estimated by Northern blot analysis. The nucleotide se­
quence of this eDNA revealed that it had a 1029 base pairs open 
reading frame corresponding to 342 amino acids and three N-linked 
glycosylation sites. Although we have not precisely determined the 
exon/intron boundary, Southern blot analysis indicated this gene to 
consist of at least five exons. 
At this point it is still questionable whether this eDNA encodes 
the melanoma antigen. In order to answer this, it is necessary to have 
this eDNA expressed on human melanoma cells. Such a project is 
now 111 progress. 
Structual Analysis of 02-18 Gene Products We have com­
pared the sequence of 02-18 with those of other oncogenes re­
ported up to now and found that there were not any genes homolo­
gous to this one. Therefore, the 02-18 is considered to be a new 
gene. Examination of the deduced amino acid sequence showed that 
this gene product possesses several characteristic features (Fig 4). 
We found many cysteine residues located preferentially in the N­
terminal portion. Some of them seemed to constitute an interesting 
structure - that is, the so-called DNA binding finger structure [19-
21 J, which is represented by repeated Cys-X-X-Cys (X represent­
ing any amino acid) or Cys-X-X-His sequences. Within these re­
peated units 10 or 12 amino acids could be observed between them 
(Fig 5). This structure is thought to create a self-sufficient folded 
domain and is stabilized by the zinc ion. This loop- or finger-like 
structure contains basic amino acids which are able to bind to DNA. 
From the above data we speculate that this gene product might be a 
DNA binding protein involved in gene regulation through tran­
scriptional control. 
A typical example of a DNA binding finger is TFIIIA, a tran­
scription factor of 5S genes of Xenopus laevis oocytes. Miller et al 
have reported that there are nine repeated Cys-X-X-Cys and 
His-X-X-His sequences and several invariant hydrophobic amino 
acids within the loop [22,23]. We found the same invariant amino 
acids within the loop structure of 02-18 as found in TFIIIA (Fig 5). 
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Figure 3. Cell surface staining profiles of cloned genomic DNA transfectants. A (left): Human melanoma cells transfected with pD2-1 (P36-D2-1) or 
pD2-2 (P36-D2-2) were stained with fluorescein isothiocyanate conjugated MS62 antibody or T141 antibody as isotype control. Staining patterns of B 16 
mouse melanoma cells and SK-Mel 28 human melanoma cells (P36) were also shown. B (ri.�lzt): Staining profiles of two independent pD2-7 transfectants of 
human melanoma cells (P36-D2-7-3, P36-D2-7-S). 
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Figure 4_ Characteristic amino acid sequences deduced on 02-18 eDNA. 
A: Arrows indicate the sites of cysteine residues and closed circles indicate the 
sites of basic amino acids. B: Closed boxes indicate the potential phosphoryla­
tIOn sites and closed circles indicate the sites of serine/threonine residues. C: 
Hatched boxes indicate N-linked glycosylation sites and asterisks show proline 
residues. The figures show the amino acid number from the N-terminal 
portion. 
In the case of TFIIIA the interval between fingers consists of 12 
amino acids which are considered to bind six nucleotides corre­
sponding to a half turn of the helix. 
There are other reports on this characteristic loop structure. 
Steroid receptors are known to have two Cys-X-X-Cys structures in 
the DNA binding domain [24,25], and the destruction of this se­
quence abolished DNA binding activity [26,27]. It is speculated that 
this structure IS very naive and is involved in the transcriptional 
activatIOn. However, at this moment we do not have any evidence 
to show that the D2-18 gene product actually binds to DNA. 
Another possibility regarding this cysteine-rich area is that it 
might be a ligand bin�ing domain. It is known that several receptor 
molecules have cysteme abundant regions in the ligand binding 
domain, such as receptors for epidermal growth factor [28], insulin 
[29]' and low-density lipoprotein [30]. They have particularly cys­
teme-lyslne-arglnlne nch sequences which are considered to bind to 
ligands. In that sense the D2-18 might be a receptor molecule for 
unidentified ligands. 
We also found that serine and threonine residues are clustered in 
the C-terminal region. Four potential phosphorylation sites by ser­
me/threonine klnases are Identified and three of them are located in 
the C-terminal areas. Although we did not examine whether this 
gene product was actually phosphorylated in vivo, the idea of po­
tential phosphorylatIOn suggests that it could be a kind of substrate 
for serine/threonine kinases and is involved in cellular responses 
because phosphorylation IS known to play a crucial role in the func­
tion or expression of proteins [31,32]. However, this particular gene 
product seems not to have a kinase activity by itself because there are 
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Figure 5. Diagram of potential DNA binding finger. Closed circles show the 
potential DNA binding amino acids and OpOI circles indicate invariant amino 
acids based on the TFIIIA sequence. Partial amino acid sequence of 02-18 
(from tenth to sixty-ninth) is also shown. 
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no potential ATP binding sites, Gly-X-Gly-X-X-Gly [33], in the 
D2-18 sequence. 
Another characteristic found in the D2-18 sequence is that it has 
many proline residues, especially in the C-terminal areas. Proline 
residues compose 10% of the total amino acids in the D2-18 gene 
product. The clustered prolines give it a compact and rigid struc­
ture, affecting its secondary structure. 
In order to investigate this gene product further, we attempted to 
produce an mRNA product by the in vitro transcription system 
powered by the SP6 promoter. The autoradiogram of the in vitro 
translation product of D2-18 cDNA showed three bands by sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). 
The largest band migrated to 46 kDa, whereas the deduced molecu­
lar weight of the D2-18 gene product is 38 kDa. This discrepancy is 
probably explained by the compact secondary structure due to the 
proline abundant regions, as described above. A similar example has 
been reported concerning the human c-myc oncogene [34]. In that 
case the deduced molecular weight was 49 kDa and the in vitro 
translation product migrated to 65 kDa in SDS-PAGE. 
Another question also exists concerning the two other bands (36 
and 34 kDa) generated by in vitro translation. At this moment we 
do not know the reason for these two extra bands, but we tend to 
speculate in the following way. There are two clustered inframe 
A TG codons near the authentic start codon. If two aberrant start 
sites are utilized in the in vitro translation system, the estimated 
molecular weight of each transcript will correspond to the results of 
SDS-PAGE, taking into consideration the effects of the abundant 
proline. 
We examined the expression of this gene and detected the same­
size transcripts in various types of cells. It is expressed in NIH/3T3 
cells and several organs of C57BL/6 origin, such as thymus, liver, 
and kidney, besides mouse and human melanomas. It is clear that the 
expression is not specific for melanoma cells, and it is suggested that 
there may very well be some differences between the D2-18 gene 
product and the counterpart gene product from normal cells. This 
reminds us of the concept of the proto-oncogene. If this were the 
case, the cellular oncogene would be very similar to the activated 
gene from B 16 melanoma cells, as seen in other oncogene families 
such as ras and src genes. Therefore, it is essential to clarify the 
structure of the normal counterpart to assess the function of this 
gene [35]. 
Another issue requiring our attention will be the human gene 
corresponding to the D2-18 gene. As there is a message detected by 
the D2-18 probe in human melanoma cells, the cloning of the 
human gene will provide us with more information about the con­
served sequence between them. Such a conserved sequence must 
possess a valuable domain for maintaining vital function(s} of the 
gene during the evolutionary process. It will also furnish us with 
useful materials for analyzing the mechanism of oncogenesis and 
can be considered as a potent tool in the clinical fields. Recombinant 
DNA technology enables us to produce a lot of gene products from 
bacteria, from which we can make monoclonal antibodies against 
oncogene products of melanoma origin. This kind of antibody will 
prove to be a useful probe for the diagnosis of cancers and possess 
potential for therapeutic applications. 
We thallk Dr. Toshitada Takemori JM valuable discussions on this project and 
Chimi Saitoh Jor her secretarial assistance. 
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